NCT00622258 - A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions

Non-Hodgkin's Lymphoma

Interventions

DRUG

Everolmus

Trial Locations (8)

Novartis Investigative Site, Nagoya

Novartis Investigative Site, Nagoya

Novartis Investigative Site, Kashiwa

Novartis Investigative Site, Chuo-ku

Novartis Investigative Site, Isehara

Novartis Investigative Site, Sendai

Novartis Investigative Site, Fukuoka

Novartis Investigative Site, Kyoto